Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells

Cytotherapy

Volumn 15, Issue 3, 2013, Pages 352-361

  Ghasemi, Mehdi ^a,c   Erturk, Murat ^a   Buruk, Kurtulus ^a   Sonmez, Mehmet ^b  

^a Medical Microbiology   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^c BILKENT UNIVERSITY   (Turkey)

Author keywords

Dendritic cells; Herpes simplex virus; Mice; Vaccine

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VACCINE; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; HERPES SIMPLEX; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TRIGEMINUS GANGLION; VIRUS IMMUNITY;

EID: 84875428916     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2012.11.012     Document Type: Article

References (63)

1. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117: 1195-203.
2. Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J Intern Med. 2011;269:64-73.
3. Asim S, Sunil KC, Kartik M, Kenneth AF, Malaya BC. Dendritic cell based vaccines for immunotherapy of cancer. Cancer Ther. 2003;1:299-314.
4. Hatfield P, Merrick AE, West E, O'Donnell D, Selby P, Vile R, et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother. 2008; 31:620-32.
5. Fry TJ, Shand JL, MilironM, Tasian SK, Mackall CL. Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. Cancer Immunol Immunother. 2009;58:1257-64.
6. Ralph MS, Jacques B. Taking dendritic cells into medicine. Nature. 2007;449:419-26.
7. Stefano MS, Filippo B. Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines. Stem Cells. 2003;21:495-505.
8. Mbow ML, Zeidner N, Panella N, Titus RG, Piesman J. Borrelia burgdorferi pulsed dendritic cells induce a protective immune response against tick-transmitted spirochetes. Infect Immun. 1997;65:3386-90.
9. Ludewig B, Ehl U, Karrer B, Odermatt H, Hengartner S, Zinkernagel RM. Dendritic cells efficiently induce protective antiviral immunity. J Virol. 1998;72:3812-8.
10. Lopez CB, Fernandez A, Sesma A, Czelusniak SM, Schulman JM, Moran TM. A mouse model for immunization with ex vivo virus-infected dendritic cells. Cellular Immunol. 2000;206:107-15.
11. Schön E, Harandi AM, Nordström I, Holmgren J, Eriksson K. Dendritic cell vaccination protects mice against lethality caused by genital herpes simplex virus type 2 infection. J Reprod Immunol. 2001;50:87-104.
12. Silvia B, Katia P, Claudia M, Roberta G, Silvia B, Emanuela B, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood J. 2003;102:3807-14.
13. Hua S, Ronald M, William W, Elizabeth F, John CP, Harlan DC. Vaccination against chlamydial genital tractinfection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med. 1998;188:809-18.
14. Ozawa Y, Suda T, Nagata T, Hashimoto D, Nakamura Y, Enomoto N, et al. Mucosal vaccine using CTL epitope-pulsed dendritic cell confers protection for intracellular pathogen. Am J Respir Cell Mol Biol. 2009;41:440-8.
15. Catherine I, Kris C. DNA vaccines: Designing strategies against parasitic infections. Genet Vaccines and Ther. 2004;2: 17-24.
16. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004;10:1359-65.
17. Zabaleta A, Llopiz D, Arribillaga L, Silva L, Riezu-Boj JI, Lasarte JJ, et al. Vaccination against hepatitis C virus with dendritic cells transduced with adenovirus encoding NS3 protein. Mol Ther. 2008;16:210-7.
18. García F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis. 2005;191:1680-5.
19. Ide F, Nakamura T, Tomizawa M, Kawana-Tachikawa A, Odawara T, Hosoya N, et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: A phase 1 trial. J Med Virol. 2006;78:711-8.
20. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization with HIV-1 peptide-loaded dendritic cells is safe and immunogenic in HIV. Clin Vaccine Immunol. 2008;15:284-92.
21. Lasarte JJ, Garcia-Granero M, Lopez A, Casares N, Garcia N, Civeira M-P, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology. 1998;2:815-22.
22. Gowans EJ, Jones KL, Bharadwaj M, Jackson DC. Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol. 2004;30:283-90.
23. Encke J, Findeklee J, Geib J, Pfaff E, Stremmel W. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol. 2005;142: 362-9.
24. Zabaleta A, Arribillaga L, Llopiz D, Dotor J, Lasarte JJ, Prieto J, et al. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I: C) and anti-CD40. Antiviral Res. 2007;74:25-35.
25. Beckebaum S, Cicinnati VR, Zhang X, Ferencik S, Frilling A, Grosse-Wilde H, et al. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: Mechanisms for viral immune escape. Immunology. 2003;109:487-95.
26. Tavakoli S, Schwerin W, Rohwer A, Hoffmann S, Weyer S, Weth R, et al. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. J Gen Virol. 2004;85:2829-36.
27. Akbar F, Furukawa S, Onji M, Murata Y, Niya T, Kanno S, et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res. 2004;29: 136-41.
28. Chen M, Li YG, Zhang D, Wang ZY, Zeng WQ, Shi XF, et al. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: A clinical study. World J Gastroenterol. 2005;11:1806-8.
29. Erturk M, Welch MJ, Phillpotts RJ, Jennings R. Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents. Vaccine. 1989;7:431-6.
30. Shi M, Qian S, Chen WW, Zhang H, Tang Zhang Z, et al. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin Exp Immunol. 2006;147:277-86.
31. Erturk M, Hill TJ, Shimeld C, Jennings R. Acute and latent infection of mice immunized with HSV-1 ISCOM vaccine. Arch Virol. 1992;125:87-101.
32. Jennings R, Erturk M. Comparative studies of HSV-1 antigens solubilised from infected cells by using non-ionic or zwitterionic detergents. J Med Virol. 1990;31:98-108.
33. Lutz MB, Kukutsch N, Ogilvie AL, Robner S, Koch K, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92.
34. Al-Ghamdi A, Jennings R, Bentley H, Potter CW. Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation. ArchVirol. 1989;108:19-31.
35. Lin WR, Jennings R, Smith TL, Wozniak MA, Itzhaki RF. Vaccination prevents latent HSV1 infection of mouse brain. Neurobiol Aging. 2001;22:699-703.
36. Harbour DA, Hill TJ, Blyth WA. Recurrent herpes simplex in the mouse: Inflammation in the skin and activation of virus in the ganglia following peripheral stimulation. J Gen Virol. 1983;64:1491-8.
37. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med. 2003;198:1023-34.
38. Gosse JA. Migration of dendritic cell based cancer vaccines: In vivo veritas. Curr Opin Immunol. 2005;17:170-4.
39. Barrat-Boyes SM, Figdor CG. Current issues in delivering DCs for immunotherapy. Cytotherapy. 2004;6:105-10.
40. Moriya O, Matsui M, Osorio M, Miyazawa H, Rice CM, Feinstone SM, et al. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine. 2001;20:789-96.
41. Yu H, Babiuk LA, van Drunen Littel-van den Hurk S. Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity. J Viral Hepatol. 2008;15:459-70.
42. Richards CM, Case R, Hirst TR, Hill TJ, Williams NA. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. J Virol. 2003;77:6692-9.
43. Quenelle DC, Collins DJ, Marciani DJ, Kern ER. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Vaccine. 2006;24:1515-22.
44. Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, et al. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. Microbiol Infect Dis. 2007;30:197-210.
45. Brans R, Akhrameyeva NV, Yao F. Prevention of genital herpes simplex virus type 1and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1. J Invest Dermatol. 2009;129:2470-9.
46. Hilfenhaus J, Moser H, Herrmann S, Mauller R. Herpes virus subunit vaccine: Characterization of the virus strain used and testing of the vaccine. Dev Biol Stand. 1982;52:321-5.
47. Kumel G, Kaerner HC, Levine M, Schroder CH, Glorioso JC. Passive immunoprotection by HSV specific monoclonal antibodies and monoclonal antibody resistant mutants altered in pathogenicity. J Virol. 1985;7:333-7.
48. Berman PW, Vogt PE, Gregory T, Lansky LA, Kern ER. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent and latent genital infections with herpes simplex virus type 2 in guinea-pigs. J Infect Dis. 1988;157:897-902.
49. Watari E, Dietzschold B, Szokan G, Heber-Katz E. A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2. J Exp Med. 1987;165:459-70.
50. Kuklin NA, Daheshia M, Chun S, Rouse BT. Role of mucosal immunity in herpes simplex virus infection. J Immunol. 1998; 160:5998-6003.
51. Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol. 1998;160:6093-7000.
52. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes. 2004;11(Suppl. 3): 161A-9A.
53. Simms JR, Heath AW, Jennings R. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs. J Infect Dis. 2000;181:1240-8.
54. Davis-Poynter NJ, Farrell HE. Masters of deception: A review of herpesvirus immune evasion strategies. Immunol Cell Biol. 1996;74:513-22.
55. Ghiassi H, Perng G, Nesburn AB, Wechsler SL. Either a CD4? or CD8?T cell function is sufficient for clearance of infectious virus from trigeminal ganglia and establishment of herpes simplex virus type 1 latency in mice. Microb Pathog. 1999;27:387-94.
56. Khanna KM, Lepisto AJ, Decman V, Hendricks RL. Immune control of herpes simplex virus during latency. Curr Opin Immunol. 2004;16:463-9.
57. Johnson AJ, Chu CF, Milligan GN. Effector CD4? T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J Virol. 2008;82: 9678-88.
58. Iijima N, Linehan MM, Zamora M, Butkus D, Dunn R, Kehry MR, et al. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med. 2008;205:3041-52.
59. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. J Virol. 2008; 82:8431-41.
60. Arvin A, Campadelli-Fiume G, Mocarski E. Herpes simplex vaccines. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al, editors. Human herpesviruses: Biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press; 2007.
61. Rupp R, Bernstein DI. The potential impact of a prophylactic herpes simplex vaccine. Expert Opin Emerg Drugs. 2008;13: 41-52.
62. Johnston C, Koelle DM, Wald A. HSV-2: In pursuit of a vaccine. J Clin Invest. 2011;121:4600-9.
63. Robert B, Belshe MD, Peter A, Leone MD, David I, Bernstein MD, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34-43.